2024-06-302025-06-292025-06-29false10208733GRIMSBY ANAESTHESIA ASSOCIATES LIMITED2026-04-28falseiso4217:GBPxbrli:pure102087332024-06-29102087332025-06-29102087332024-06-302025-06-29102087332023-06-29102087332024-06-29102087332023-06-302024-06-2910208733bus:SmallEntities2024-06-302025-06-2910208733bus:AuditExempt-NoAccountantsReport2024-06-302025-06-2910208733bus:FullAccounts2024-06-302025-06-2910208733bus:PrivateLimitedCompanyLtd2024-06-302025-06-2910208733core:WithinOneYear2025-06-2910208733core:AfterOneYear2025-06-2910208733core:WithinOneYear2024-06-2910208733core:AfterOneYear2024-06-2910208733core:ShareCapital2025-06-2910208733core:SharePremium2025-06-2910208733core:RevaluationReserve2025-06-2910208733core:OtherReservesSubtotal2025-06-2910208733core:RetainedEarningsAccumulatedLosses2025-06-2910208733core:ShareCapital2024-06-2910208733core:SharePremium2024-06-2910208733core:RevaluationReserve2024-06-2910208733core:OtherReservesSubtotal2024-06-2910208733core:RetainedEarningsAccumulatedLosses2024-06-2910208733core:LandBuildings2025-06-2910208733core:PlantMachinery2025-06-2910208733core:Vehicles2025-06-2910208733core:FurnitureFittings2025-06-2910208733core:OfficeEquipment2025-06-2910208733core:NetGoodwill2025-06-2910208733core:IntangibleAssetsOtherThanGoodwill2025-06-2910208733core:ListedExchangeTraded2025-06-2910208733core:UnlistedNon-exchangeTraded2025-06-2910208733core:LandBuildings2024-06-2910208733core:PlantMachinery2024-06-2910208733core:Vehicles2024-06-2910208733core:FurnitureFittings2024-06-2910208733core:OfficeEquipment2024-06-2910208733core:NetGoodwill2024-06-2910208733core:IntangibleAssetsOtherThanGoodwill2024-06-2910208733core:ListedExchangeTraded2024-06-2910208733core:UnlistedNon-exchangeTraded2024-06-2910208733core:LandBuildings2024-06-302025-06-2910208733core:PlantMachinery2024-06-302025-06-2910208733core:Vehicles2024-06-302025-06-2910208733core:FurnitureFittings2024-06-302025-06-2910208733core:OfficeEquipment2024-06-302025-06-2910208733core:NetGoodwill2024-06-302025-06-2910208733core:IntangibleAssetsOtherThanGoodwill2024-06-302025-06-2910208733core:ListedExchangeTraded2024-06-302025-06-2910208733core:UnlistedNon-exchangeTraded2024-06-302025-06-2910208733core:MoreThanFiveYears2024-06-302025-06-2910208733core:Non-currentFinancialInstruments2025-06-2910208733core:Non-currentFinancialInstruments2024-06-2910208733dpl:CostSales2024-06-302025-06-2910208733dpl:DistributionCosts2024-06-302025-06-2910208733core:LandBuildings2024-06-302025-06-2910208733core:PlantMachinery2024-06-302025-06-2910208733core:Vehicles2024-06-302025-06-2910208733core:FurnitureFittings2024-06-302025-06-2910208733core:OfficeEquipment2024-06-302025-06-2910208733dpl:AdministrativeExpenses2024-06-302025-06-2910208733core:NetGoodwill2024-06-302025-06-2910208733core:IntangibleAssetsOtherThanGoodwill2024-06-302025-06-2910208733dpl:GroupUndertakings2024-06-302025-06-2910208733dpl:ParticipatingInterests2024-06-302025-06-2910208733dpl:GroupUndertakingscore:ListedExchangeTraded2024-06-302025-06-2910208733core:ListedExchangeTraded2024-06-302025-06-2910208733dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-06-302025-06-2910208733core:UnlistedNon-exchangeTraded2024-06-302025-06-2910208733dpl:CostSales2023-06-302024-06-2910208733dpl:DistributionCosts2023-06-302024-06-2910208733core:LandBuildings2023-06-302024-06-2910208733core:PlantMachinery2023-06-302024-06-2910208733core:Vehicles2023-06-302024-06-2910208733core:FurnitureFittings2023-06-302024-06-2910208733core:OfficeEquipment2023-06-302024-06-2910208733dpl:AdministrativeExpenses2023-06-302024-06-2910208733core:NetGoodwill2023-06-302024-06-2910208733core:IntangibleAssetsOtherThanGoodwill2023-06-302024-06-2910208733dpl:GroupUndertakings2023-06-302024-06-2910208733dpl:ParticipatingInterests2023-06-302024-06-2910208733dpl:GroupUndertakingscore:ListedExchangeTraded2023-06-302024-06-2910208733core:ListedExchangeTraded2023-06-302024-06-2910208733dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-06-302024-06-2910208733core:UnlistedNon-exchangeTraded2023-06-302024-06-2910208733core:NetGoodwill2025-06-2910208733core:IntangibleAssetsOtherThanGoodwill2025-06-2910208733core:LandBuildings2025-06-2910208733core:PlantMachinery2025-06-2910208733core:Vehicles2025-06-2910208733core:FurnitureFittings2025-06-2910208733core:OfficeEquipment2025-06-2910208733core:AfterOneYear2025-06-2910208733core:WithinOneYear2025-06-2910208733core:ListedExchangeTraded2025-06-2910208733core:UnlistedNon-exchangeTraded2025-06-2910208733core:ShareCapital2025-06-2910208733core:SharePremium2025-06-2910208733core:RevaluationReserve2025-06-2910208733core:OtherReservesSubtotal2025-06-2910208733core:RetainedEarningsAccumulatedLosses2025-06-2910208733core:NetGoodwill2024-06-2910208733core:IntangibleAssetsOtherThanGoodwill2024-06-2910208733core:LandBuildings2024-06-2910208733core:PlantMachinery2024-06-2910208733core:Vehicles2024-06-2910208733core:FurnitureFittings2024-06-2910208733core:OfficeEquipment2024-06-2910208733core:AfterOneYear2024-06-2910208733core:WithinOneYear2024-06-2910208733core:ListedExchangeTraded2024-06-2910208733core:UnlistedNon-exchangeTraded2024-06-2910208733core:ShareCapital2024-06-2910208733core:SharePremium2024-06-2910208733core:RevaluationReserve2024-06-2910208733core:OtherReservesSubtotal2024-06-2910208733core:RetainedEarningsAccumulatedLosses2024-06-2910208733core:NetGoodwill2023-06-2910208733core:IntangibleAssetsOtherThanGoodwill2023-06-2910208733core:LandBuildings2023-06-2910208733core:PlantMachinery2023-06-2910208733core:Vehicles2023-06-2910208733core:FurnitureFittings2023-06-2910208733core:OfficeEquipment2023-06-2910208733core:AfterOneYear2023-06-2910208733core:WithinOneYear2023-06-2910208733core:ListedExchangeTraded2023-06-2910208733core:UnlistedNon-exchangeTraded2023-06-2910208733core:ShareCapital2023-06-2910208733core:SharePremium2023-06-2910208733core:RevaluationReserve2023-06-2910208733core:OtherReservesSubtotal2023-06-2910208733core:RetainedEarningsAccumulatedLosses2023-06-2910208733core:AfterOneYear2024-06-302025-06-2910208733core:WithinOneYear2024-06-302025-06-2910208733core:Non-currentFinancialInstrumentscore:CostValuation2024-06-302025-06-2910208733core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-06-302025-06-2910208733core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-06-302025-06-2910208733core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-06-302025-06-2910208733core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-06-302025-06-2910208733core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-06-302025-06-2910208733core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-06-302025-06-2910208733core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-06-302025-06-2910208733core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-06-302025-06-2910208733core:Non-currentFinancialInstrumentscore:CostValuation2025-06-2910208733core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-06-2910208733core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-06-2910208733core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-06-2910208733core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-06-2910208733core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-06-2910208733core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-06-2910208733core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-06-2910208733core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-06-2910208733core:Non-currentFinancialInstrumentscore:CostValuation2024-06-2910208733core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-06-2910208733core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-06-2910208733core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-06-2910208733core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-06-2910208733core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-06-2910208733core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-06-2910208733core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-06-2910208733core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-06-2910208733bus:Director12024-06-302025-06-2910208733bus:Director22024-06-302025-06-2910208733core:FurnitureFittingsToolsEquipment2024-06-2910208733core:FurnitureFittingsToolsEquipment2024-06-302025-06-2910208733core:FurnitureFittingsToolsEquipment2025-06-29

GRIMSBY ANAESTHESIA ASSOCIATES LIMITED

Registered Number
10208733
(England and Wales)

Unaudited Financial Statements for the Year ended
29 June 2025

GRIMSBY ANAESTHESIA ASSOCIATES LIMITED
Company Information
for the year from 30 June 2024 to 29 June 2025

Directors

SHAHBAZ, Muhammad, Dr
SHAHBAZ, Shumaila, Dr

Company Secretary

FAQIR, Hafsah Mobeen

Registered Address

9 Lea Drive
Grimsby
DN32 9FB

Registered Number

10208733 (England and Wales)
GRIMSBY ANAESTHESIA ASSOCIATES LIMITED
Balance Sheet as at
29 June 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Tangible assets32,4543,005
2,4543,005
Current assets
Debtors4126,750158,219
Cash at bank and on hand32,236480
158,986158,699
Creditors amounts falling due within one year5(5,509)(8,983)
Net current assets (liabilities)153,477149,716
Total assets less current liabilities155,931152,721
Net assets155,931152,721
Capital and reserves
Called up share capital400400
Profit and loss account155,531152,321
Shareholders' funds155,931152,721
The financial statements were approved and authorised for issue by the Board of Directors on 28 April 2026, and are signed on its behalf by:
SHAHBAZ, Muhammad, Dr
Director
SHAHBAZ, Shumaila, Dr
Director

Registered Company No. 10208733
GRIMSBY ANAESTHESIA ASSOCIATES LIMITED
Notes to the Financial Statements
for the year ended 29 June 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Current taxation
Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income. Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Straight line (years)
Fixtures and fittings5
Office Equipment5
Trade and other debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Trade and other creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Share capital
Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.
2.Average number of employees

20252024
Average number of employees during the year32
3.Tangible fixed assets

Fixtures & fittings

Office Equipment

Total

£££
Cost or valuation
At 30 June 242,4354,3146,749
Additions-999999
At 29 June 252,4355,3137,748
Depreciation and impairment
At 30 June 241,7961,9483,744
Charge for year4871,0631,550
At 29 June 252,2833,0115,294
Net book value
At 29 June 251522,3022,454
At 29 June 246392,3663,005
4.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables-6,603
Other debtors126,750151,616
Total126,750158,219
5.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables1,000432
Bank borrowings and overdrafts27-
Taxation and social security3,6098,518
Other creditors3333
Accrued liabilities and deferred income840-
Total5,5098,983
Included within bank borrowings and overdrafts is an amount payable of £27 to the directors (2024: £24,865 receivable included within other debtors).
6.Share capital
400 Ordinary Shares